Background Some patients with asthma have frequent exacerbations and persistent airflow
obstruction despite treatment with inhaled glucocorticoids and long-acting beta-agonists (…

Background In patients with severe asthma, tiotropium improves lung function and exacerbation
risk when added to high-dose inhaled corticosteroids plus long-acting β 2 agonists. We …

… : P = .02 for 5 μg of tiotropium and P = .17 for 2.5 μg of tiotropium vs placebo at week 24;
P = .15 for 5 μg of tiotropium and P = .58 for 2.5 μg of tiotropium vs placebo at week 48; Fig 4). …

Background Studies in adults and adolescents have demonstrated that tiotropium is efficacious
as an add-on therapy to inhaled corticosteroids (ICSs) with or without other maintenance …

We present results from the first phase III trial of once-daily tiotropium add-on to inhaled
corticosteroids (ICS) plus one or more controller therapies in adolescents with severe …

Background Many patients with asthma remain symptomatic despite treatment with inhaled
corticosteroids (ICS) with or without long-acting β 2 -agonists (LABAs). Tiotropium add-on to …

Background Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has demonstrated
efficacy in patients with asthma who were symptomatic despite treatment with medium…

… versus placebo (p = 0.0043). Trough FEV 1 responses were significantly greater for tiotropium
5 μg (p < 0.00001) and 1.25 μg (p = 0.0134) versus placebo, but not for 2.5 μg (p = 0.0975)…

Background A considerable number of children with asthma remain symptomatic despite
treatment with inhaled corticosteroids, resulting in significant morbidity, reduced quality of life, …

Background This study assessed the long-term safety and efficacy of tiotropium Respimat, a
long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled …